DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 022484
» See Plans and Pricing
The generic ingredient in ONMEL is itraconazole. There are fifteen drug master file entries for this compound. Additional details are available on the itraconazole profile page.
Summary for 022484
Tradename: | ONMEL |
Applicant: | Sebela Ireland Ltd |
Ingredient: | itraconazole |
Patents: | 1 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 022484
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
Approval Date: | Apr 29, 2010 | TE: | RLD: | Yes | |||||
Patent: | Start Trial | Patent Expiration: | Oct 3, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022484
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | ONMEL | itraconazole | TABLET;ORAL | 022484-001 | Apr 29, 2010 | Start Trial | Start Trial |
Sebela Ireland Ltd | ONMEL | itraconazole | TABLET;ORAL | 022484-001 | Apr 29, 2010 | Start Trial | Start Trial |
Sebela Ireland Ltd | ONMEL | itraconazole | TABLET;ORAL | 022484-001 | Apr 29, 2010 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription